Drug Profile
VCN 02
Alternative Names: VCN-02Latest Information Update: 01 Jun 2022
Price :
$50
*
At a glance
- Originator VCN Biosciences
- Class Antineoplastics; Oncolytic viruses
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 01 Jun 2022 VCN 02 is still in preclinical development for Cancer in Spain (VCN Biosciences pipeline, June 2022)
- 11 Mar 2022 VCN Biosciences has been acquired by Synthetic Biologics
- 28 Feb 2021 No recent reports of development identified for preclinical development in Cancer in Spain (Parenteral)